Tenaya Therapeutics(TNYA) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update Data Safety and Monitoring Board Endorsed Dose Escalation and Broadening of Inclusion Criteria in the MyPEAK TM-1 Phase 1b/2 Trial of TN-201 Gene Therapy Initial TN-201 Data from Cohort 1 of MyPEAK-1 to be Reported in December 2024 SOUTH SAN FRANCISCO, Calif., November 6, 2024 – Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deli ...